Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HLA-A*02:01/p53 R175H bispecific T-cell engager CLSP-1025

An asymmetric bispecific single-chain diabody (scDb) Fc fusion protein and T-cell engager (TCE) directed against the human TP53 (p53) R175H mutant peptide (p53(R175H)168-176) bound to human leukocyte antigen (HLA)-A*02:01 (HLA-A*02:01) and the T-cell-specific antigen CD3epsilon (CD3e), with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A*02:01/p53 R175H bispecific TCE CLSP-1025 specifically targets and binds to CD3 on cytotoxic T lymphocytes (CTLs) with its anti-CD3 domain and the p53(R175H)168-176 mutant peptide bound to HLA-A*02:01 expressed on tumor cells with its anti-peptide HLA (pHLA) domain. This activates and redirects CTLs to HLA-A*02:01/p53 R175H-expressing tumor cells, which results in the CTL-mediated cell death of these p53 R175H-expressing tumor cells. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.
Synonym:anti-p53 R175H T-cell engager CLSP-1025
anti-p53 R175H TCE CLSP-1025
anti-p53 R175H/CD3 fusion protein CLSP-1025
bispecific T-cell engager anti-HLA-A*02:01/p53 R175H CLSP-1025
bispecific TCE CLSP-1025
p53 R175H/HLA-A*02:01-specific T-cell engager CLSP-1025
pHLAre (TM) CLSP-1025
precise HLA redirecting engager CLSP-1025
Code name:CLSP 1025
CLSP-1025
CLSP1025
Search NCI's Drug Dictionary